top of page
Espacio de trabajo moderna

STRATEGIC CONSULTING SERVICES 

YOUR PARTNER, EVERY STEP OF THE WAY

CLINICAL TRIAL STRATEGY 

We're looking for you

Collaborate with us to improve patient care as fast and cost-efficient as possible. 

 

At MEDSIR, we leverage our relationships, access to services, and strategic perspective to become an invaluable partner in every step of the development of your asset. Trust us to bring our expertise and passion for innovation to your project to put it on the path to success. 

>31
INDUSTRY FUNDERS

>48
ONCOLOGY TRIALS

>232  
SITES

>432  
RESEARCH
COLLABORATORS

>400 
IDEAS
GENERATED

>88  
STAFF
DEDICATED

>2310 
PATIENTS
RECRUITED

CLINICAL DEVELOPMENT CONSULTING 

We're looking for you

Our Strategic Services guide clients through planning, managing, analyzing, and reporting clinical trials. We believe that success is a team effort, and we’ll be with you along the way to ensure that your project achieves the desired outcomes. 

Icon_Results bg.png

SET UP NEW TRIALS. Utilizing our network of Key Opinion Leaders (KOLs), we can develop your clinical strategy and complete trial roadmap, including study design and protocol optimization. We prioritize collaboration and work closely with you to maintain the key interests of your company throughout the process. 

SERVICES INCLUDE: Think Tanks for pharma companies, Advisory Boards for biotech companies, Expert Committees 
 

 

WHY CHOOSE MEDSIR?

home_fondo_tolife_barra.jpg
  • Network of oncology experts and KOLs who provide feedback on your pipeline 

  • Multinational operational structure that is not limited by a pre-defined network of sites 

  • Flexible clinical development support to fit your needs 

  • Consultative support to develop end-to-end clinical trial strategies 

SOME OF OUR CLINICAL TRIALS

We're looking for you
3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

PHERGAIN

BREAST

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: A FDG-PET response-adapted strategy

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

SLLIP

LUNG

Spanish Lung Liquid vs. Invasive biopsy Program (SLLIP)

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

ORPHEUS

PENIS

Phase II Study of the Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

PARSIFAL

BREAST

Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer

SOME CLINICAL EXPERTS COLLABORATING
WITH MEDSIR

We're looking for you

JAVIER

CORTÉS

Medical Oncologist 
MD, PhD

PETER SCHMID

Medical Oncologist MD, PhD

ANTONIO

LLOMBART

Medical Oncologist 
MD, PhD

JORDI 

REMON

Medical Oncologist 
MD, PhD

MARTA 
VAZ-BAPTISTA

Medical Oncologist 
MD

JOSEPH GLIGOROV

Medical Oncologist 
MD, PhD

FREDERIK MARMÉ

Gynecologist 
MD

NOEMÍ REGUART

Medical Oncologist 
MD, PhD

MARINA GARASSINO

Medical Oncologist 
MD, PhD

PETER

KAUFMAN

Medical Oncologist 
MD

JOAN CARLES

Medical Oncologist 
MD, PhD

JOSEP MARIA

PIULATS

Medical

Oncologist 
MD, PhD

NIKI KARACHALIOU

Medical Oncologist 
MD, PhD

JOSÉ
PÉREZ

Medical Oncologist 
MD, PhD

ANTONIO

CALLES

Medical Oncologist MD, PhD

JAVIER GARDE

Medical Oncologist 
MD

COLLABORATORS FROM INDUSTRY AND ACADEMIA

home_fondo_you_barra_edited.jpg

FREQUENTLY ASKED QUESTIONS

home_fondo_you_barra.jpg
  • WHY IS MEDSIR THE SPONSOR?
    Science is our goal. We are not a CRO. We only run studies with strategies and molecules we truly believe in. ▪ Agility in bureaucracy with agencies, steering committees and vendors is key so that we can adapt the initial plan when new risks are identified. Also, as the sponsor we can streamline the management of the clinical trial. ▪ We favor a collaborative approach for clinical research. Even if MEDSIR acts as the Sponsor, collaborating companies are involved in all relevant scientific and operational decisions, and can even be part of the Steering Committee. Likewise, the final trial database is fully shared with collaborating companies. ▪ Acting as a Sponsor allows us not to charge consultant fees since technically, we are asking for financial support from the company to run a MEDSIR study. ▪ Some operational costs can be reduced for independent studies in which the sponsor has no commercial interest.
  • WHO HAS THE INTELLECTUAL PROPERTY? WILL MEDSIR HAVE EXPLOITATION RIGHTS?
    ▪ The data collected in a clinical trial belongs to the Sponsor. However, we are willing to grant full access to all the data generated in the trial (not only published results, but the full database) to collaborating companies in perpetuity and free of any additional charges. ▪ All exploitation rights belong to the collaborating company. We are completely independent and have no commercial interests in the result of the trial. The company has access to any data needed for potential submissions to regulatory agencies. ▪ We maintain publication rights for the trial results, but the collaborating company can be included if they choose. ▪ We are interested in science. We might want to generate additional research/publications with the data collected, but we will never do it without the company’s knowledge.
  • WHAT IS THE ADDED VALUE OF MEDSIR VS COMMON INSTITUTIONS THAT PROMOTE ACADEMIC CLINICAL RESEARCH?
    ▪ We have a global operational structure. ▪ We have a flexible model which is not limited to any pre-defined network of sites and/or investigators. We involve the sites that make more sense for each particular project. ▪ We believe in collaborative clinical research. We want to consider the strategic needs of collaborating companies and are willing to involve them in all relevant decisions regarding the design and management of the project. ▪ We strive to professionalize independent clinical research applying industry quality standards. ▪ We are very agile in the presentation and development of potential ideas. Time is of the essence in the volatile field of clinical development in oncology.
  • WHAT IS THE ADDED VALUE OF CHOOSING MEDSIR VS A CRO?
    ▪ We generate added value with our scientific expertise through the initial idea generation and design. ▪ We present closed budgets with shared risk, so trial speed is in our own interest. ▪ Our model streamlines clinical research to increase speed and reduce costs. ▪ We are very proactive in controlling risks and adapting the operational plan to changing needs, if needed. We are fighting for OUR STUDY. ▪ We guarantee the full engagement of KOLs who thoroughly believe in the scientific and clinical potential of the proposals they help develop. ▪ We understand that time spent from first idea generation until start-up is crucial (maybe even more so than accrual speed).
  • WHOM DO I NEED TO CONTACT TO LEARN MORE ON HOW MEDSIR’S MODEL CAN HELP TO DEVELOP MY PIPELINE?
    Our team is available when you need it. Just fill out this form, and we will contact you as soon as possible.
We're looking for you

INSIGHTS

bottom of page